A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice Source: Eur Respir J 2012; 40: 1475-1482 Year: 2012
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by regulating inflammatory cytokines in bronchoalveolar fluid Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013
CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018
Regulation of inflammation process in chronic thromboembolic pulmonary hypertension: a potential role of platelet-activating factor-acetylhydrolase Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006
Erythromycin inhibits neutrophil extracellular traps in smoking-related chronic pulmonary inflammation Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
Roles of α1-acid glycoprotein in therapeutic effects of imatinib in bleomycin-induced pulmonary fibrosis: benefits of macrolides Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair Year: 2007
Neutrophil elastase is necessary for increases in active TGF-β in bleomycin-induced pulmonary fibrosis Source: Eur Respir J 2001; 18: Suppl. 33, 199s Year: 2001
Usefulness of selective neutrophil elastase inhibitor, sivelestat, in ALI patients with SIRS Source: Annual Congress 2012 - How to use technology to provide better critical care Year: 2012
The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017
Neutrophil apoptosis and systemic inflammatory markers in acute exacerbation of COPD Source: Eur Respir J 2003; 22: Suppl. 45, 572s Year: 2003
Evaluation of novel LOXL2-selective inhibitors in models of pulmonary fibrosis Source: International Congress 2017 – Cellular signalling pathways in pulmonary fibrosis Year: 2017
A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation Source: Eur Respir J, 53 (6) 1900303; 10.1183/13993003.00303-2019 Year: 2019
Effects of chronic nitric oxide inhibition on eosinophil recruitment and extracellular matrix remodelling in chronic pulmonary inflammation Source: Eur Respir J 2007; 30: Suppl. 51, 735s Year: 2007
Hsp90 binding inhibitors improve survival in a murine model of sepsis induced acute lung injury Source: Annual Congress 2006 - Novel pathogenic aspects of acute lung injury and acute respiratory distress syndrome (ARDS) Year: 2006
Personalised anti-inflammatory therapy for bronchiectasis and cystic fibrosis: selecting patients for controlled trials of neutrophil elastase inhibition Source: ERJ Open Res, 5 (1) 00252-2018; 10.1183/23120541.00252-2018 Year: 2019
FIZZ1: a new pathway in silica-induced inflammatory mediators and pulmonary fibrosis Source: International Congress 2018 – Occupational and environmental lung diseases: mechanisms, biomarkers and causation Year: 2018
High mobility group box protein 1 (HMGB1) production in highly vascularized alveolar lesions causes acute exacerbation in idiopathic pulmonary fibrosis Source: Annual Congress 2005 - Progresses in lung fibrosis Year: 2005
Influence of infection and α1-proteinase inhibitor on inflammatory response in COPD exacerbation Source: Eur Respir J 2003; 22: Suppl. 45, 417s Year: 2003
Pathogenesis of idiopathic pulmonary fibrosis: role of neutrophil inflammation Source: Eur Respir J 2006; 28: Suppl. 50, 102s Year: 2006